TY - JOUR
T1 - The DoloTest® in a specialized headache center among patients receiving psychological treatment
T2 - A pilot study
AU - Nielsen, Marianne Kromann
AU - Westergaard, Maria Lurenda
AU - Nielsen, Dorte Kjeldgaard
AU - Zimmer, Trine
AU - Jensen, Rigmor Hoejland
PY - 2018/7/26
Y1 - 2018/7/26
N2 - The DoloTest is a newer health-related quality of life (HRQoL) monitoring instrument for pain, not yet validated for headache. To examine the usefulness of the DoloTest in a specialized headache center. The sample consisted of patients referred to psychologists from the Danish Headache Center (DHC) for whom the test was carried out at start of, end of, and 6 months after treatment. Points on eight scales of the test were measured (values ranged from 0 to 100), then totaled (0 to 800). Scores were analyzed using Wilcoxon Signed Ranks test. The correlation between headache days and DoloTest scores were computed using linear regression adjusted for age. Qualitative feedback on usefulness of the test were gathered from psychologists. Of 135 patients included, 105 completed treatment. On average, headache days decreased from 22 days per month at start of treatment (SD 9.0, median 29) to 18 days at end of treatment (SD 10.8, median 19) (p<0.001). At end of treatment, DoloTest scores improved for pain (p=0.015) and reduced energy and strength (p=0.034). At 6 months' follow-up, total scores improved (p=0.034), as well as component scores for pain (p=0.010), problems with strenuous activity (p=0.045) and reduced energy and strength (p=0.012). Correlation between reduced headache days and improved DoloTest scores was 0.303 (p=0.028). Psychologists found the test useful in monitoring and evaluating patients. The DoloTest was useful for psychoeducation and for monitoring the effect of headache treatment. The DoloTest is a potential HRQoL monitoring instrument for headache patients. We recommend further validation studies.
AB - The DoloTest is a newer health-related quality of life (HRQoL) monitoring instrument for pain, not yet validated for headache. To examine the usefulness of the DoloTest in a specialized headache center. The sample consisted of patients referred to psychologists from the Danish Headache Center (DHC) for whom the test was carried out at start of, end of, and 6 months after treatment. Points on eight scales of the test were measured (values ranged from 0 to 100), then totaled (0 to 800). Scores were analyzed using Wilcoxon Signed Ranks test. The correlation between headache days and DoloTest scores were computed using linear regression adjusted for age. Qualitative feedback on usefulness of the test were gathered from psychologists. Of 135 patients included, 105 completed treatment. On average, headache days decreased from 22 days per month at start of treatment (SD 9.0, median 29) to 18 days at end of treatment (SD 10.8, median 19) (p<0.001). At end of treatment, DoloTest scores improved for pain (p=0.015) and reduced energy and strength (p=0.034). At 6 months' follow-up, total scores improved (p=0.034), as well as component scores for pain (p=0.010), problems with strenuous activity (p=0.045) and reduced energy and strength (p=0.012). Correlation between reduced headache days and improved DoloTest scores was 0.303 (p=0.028). Psychologists found the test useful in monitoring and evaluating patients. The DoloTest was useful for psychoeducation and for monitoring the effect of headache treatment. The DoloTest is a potential HRQoL monitoring instrument for headache patients. We recommend further validation studies.
U2 - 10.1515/sjpain-2018-0033
DO - 10.1515/sjpain-2018-0033
M3 - Journal article
C2 - 29870397
SN - 1877-8860
VL - 18
SP - 431
EP - 439
JO - Scandinavian Journal of Pain
JF - Scandinavian Journal of Pain
IS - 3
ER -